Syndax Pharmaceuticals SNDX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's retained earnings?
- Syndax Pharmaceuticals (SNDX) reported retained earnings of -$1.55B in Q1 2026.
- How has Syndax Pharmaceuticals's retained earnings changed year-over-year?
- Syndax Pharmaceuticals's retained earnings decreased by 18.6% year-over-year, from -$1.31B to -$1.55B.
- What is the long-term trend for Syndax Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's retained earnings has grown at a 21.5% compound annual growth rate (CAGR), from -$568.63M to -$1.51B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.